January 26, 2015 5:36 PM ET

Biotechnology

Company Overview of Nabi Biopharmaceuticals

Company Overview

As of October 30, 2012, Nabi Biopharmaceuticals was acquired by Biota Holdings Limited, in a reverse merger transaction. Nabi Biopharmaceuticals, a biopharmaceutical company, focuses on the development of vaccines for unmet medical needs, including nicotine addiction. The company engages in developing NicVAX, a proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. It has an option and licensing agreement with GlaxoSmithKline Biologicals S.A. to develop, commercialize, and manufacture NicVAX and follow-on nicotine addiction vaccines; a license agreement with National Institutes of Health to use rEPA carrier ...

12276 Wilkins Avenue

Rockville, MD 20852

United States

Founded in 1967

16 Employees

Phone:

301-770-3099

Fax:

301-770-3097

Key Executives for Nabi Biopharmaceuticals

Nabi Biopharmaceuticals does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
Ocean Genetics Inc. United States
Nano Precision Medical, Inc. United States
EndoBiologics International Corporation United States
AMPRO Products, Inc. United States
Integenx Acquisition Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Nabi Biopharmaceuticals, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.